Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
8.19
-0.16 (-1.92%)
Jul 23, 2026, 4:00 PM EDT - Market closed
AVR Revenue
Anteris Technologies Global had revenue of $494.00K in the quarter ending March 31, 2026, a decrease of -11.15%. This brings the company's revenue in the last twelve months to $1.85M, down -25.75% year-over-year. In the year 2025, Anteris Technologies Global had annual revenue of $1.91M, down -29.23%.
Revenue (ttm)
$1.85M
Revenue Growth
-25.75%
P/S Ratio
431.20
Revenue / Employee
$10,638
Employees
174
Market Cap
798.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.91M | -790.00K | -29.23% |
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| Azenta | 596.48M |
| AtriCure | 569.62M |
| AngioDynamics | 320.17M |
| STAAR Surgical Company | 290.38M |
| LeMaitre Vascular | 256.28M |
| OraSure Technologies | 113.02M |
| BioLife Solutions | 101.66M |
AVR News
- 22 days ago - Anteris Technologies files to sell 5.39M shares of common stock - TheFly
- 6 weeks ago - Anteris Technologies cleared by ANSM for DurAVR THV trial - TheFly
- 6 weeks ago - Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance - GlobeNewsWire
- 2 months ago - Anteris Technologies price target raised to $18 from $17 at Barclays - TheFly
- 2 months ago - Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - GlobeNewsWire
- 2 months ago - Anteris Announces Results for the First Quarter of 2026 - GlobeNewsWire
- 2 months ago - Anteris Technologies: First U.S. patients treated in global PARADIGM trial - TheFly
- 2 months ago - Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - GlobeNewsWire